ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

• Status: Completed
• Trial end date: 2018-03-28
• Target enrollment: 0
• Participant gender: All

Summary

Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Ioannina
• Treatments: Aspirin; Salicylates; Triflusal

Criteria

Inclusion Criteria:

• Patients with a stable coronary artery disease (CAD)

• Patients with a history of non-cardioembolic ischemic stroke.

Exclusion Criteria:

• Hypersensitivity reaction or contraindication to triflusal or aspirin

• Active bleeding or history of severe bleeding (peptic ulcer, trauma or intracranial hemorrhage)

• Blood coagulation disorders

• Uncontrolled severe hypertension

• Pregnancy or breastfeeding

• Liver disease (alanine or aspartate aminotransferase more than 3 times the upper normal limit)

• Malignancy that may potentially increase the risk of hemorrhage

• Drug or alcohol abuse

• HIV infection

• Chronic disorders requiring long-term treatment with systemic nonsteroidal anti-inflammatory drugs (NSAIDs).